echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: A summary analysis of clinical studies of FOLFOXIRI and Beval single anti-treatment metastatic colorectal cancer.

    Br J Cancer: A summary analysis of clinical studies of FOLFOXIRI and Beval single anti-treatment metastatic colorectal cancer.

    • Last Update: 2020-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    FOLFOXIRI (5-fluorouracil, L-folate, oxaliplatin and iriticon)/bevizumab,bev has been shown to be an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC).
    , however, pre-exposure to three types of cytotoxicity raises concerns about the effectiveness of treatment after the disease develops.
    the study, which provided a summary analysis of the therapeutic effects of FOLFOXIRI/bev in patients participating in two random phase 3 clinical trials (TRIBE and TRIBE2), compared the effects of FOLFOXIRI/bev and doublets (FOLFOX (5-fluorouracil, L-floric acid and oxaliplatin) or FOLFIRI (5-fluorouracil, L-leafic acid, and irithion) /bev.
    and assessed the rate of remission, progression-free lifetime (second PFS) and total lifetime (second OS) during treatment.
    -line RECIST (Solid Tumor Efficacy Evaluation Standard) response and OIFI (no Osaliplatin and Irithicon intervals) are potential predictive indicators for reintroduction of FOLFOXIRI±bev.
    triBE and TRIBE2 summary analysis flowchart shows that patients who received FOLFOXIRI±±bev had a longer second PFS (4.4 months, 3.9 months, and 6.1 months), and appears to be limited to patients who have received remission in first-line treatment (4.2 months and 4.7 months for 6.9 months), and OIFI ≥4 months for patients (6.5 months, 4.6 months and 7.2 months, respectively).
    second PFS and phase II OS results after first-line FOLFOXIRI/bev therapy, first-line FOLFOXIRI/bev did not affect the efficacy of second-line therapy.
    first-line reaction and longer OIFI were associated with improved response, second PFS and reintroduity of FOLFOXIRI±bev treatment strategies, but did not affect the second OS phase.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.